STOCK TITAN

[SCHEDULE 13G/A] Wave Life Sciences Ltd. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary

Adage Capital Management, L.P., together with Robert Atchinson and Phillip Gross, reports beneficial ownership of 15,016,500 ordinary shares of Wave Life Sciences, representing 9.65% of the class based on 155,562,665 ordinary shares outstanding as reported in the company's proxy. The filing is submitted on Schedule 13G (Amendment No. 4) and shows 0 sole voting or dispositive power and 15,016,500 shares of shared voting and dispositive power, held through Adage Capital Partners, L.P.

The filing includes a certification that the securities were acquired and are held in the ordinary course of business and were not acquired to change or influence control of the issuer, indicating a stated passive investment intent.

Adage Capital Management, L.P., insieme a Robert Atchinson e Phillip Gross, segnala la titolarità beneficiaria di 15,016,500 azioni ordinarie di Wave Life Sciences, rappresentanti il 9.65% della categoria in base a 155,562,665 azioni ordinarie in circolazione come indicato nella proxy della società. La comunicazione è presentata sul Schedule 13G (Emendamento n. 4) e riporta 0 poteri di voto o di disposizione in via esclusiva e 15,016,500 azioni con poteri di voto e di disposizione condivisi, detenute tramite Adage Capital Partners, L.P.

La documentazione include una certificazione secondo cui i titoli sono stati acquisiti e sono detenuti nell'ordinario corso dell'attività e non sono stati acquistati per modificare o influenzare il controllo dell'emittente, indicando un intento di investimento dichiaratamente passivo.

Adage Capital Management, L.P., junto con Robert Atchinson y Phillip Gross, comunica la titularidad beneficiaria de 15,016,500 acciones ordinarias de Wave Life Sciences, que representan el 9.65% de la clase sobre la base de 155,562,665 acciones ordinarias en circulación, según consta en el proxy de la compañía. La presentación se realiza en el Schedule 13G (Enmienda n.º 4) y muestra 0 poder exclusivo de voto o de disposición y 15,016,500 acciones con poder de voto y de disposición compartido, mantenidas a través de Adage Capital Partners, L.P.

La presentación incluye una certificación de que los valores fueron adquiridos y se mantienen en el curso ordinario del negocio y no fueron adquiridos para cambiar o influir en el control del emisor, lo que indica una intención de inversión declaradamente pasiva.

Adage Capital Management, L.P.는 Robert Atchinson 및 Phillip Gross와 함께 Wave Life Sciences의 15,016,500 보통주에 대한 실질적 소유를 보고하며, 이는 회사의 프록시에 기재된 155,562,665 발행 보통주를 기준으로 해당 계급의 9.65%에 해당합니다. 이 제출은 Schedule 13G(수정서 4호)로 이루어졌으며, 0의 단독 의결권 또는 처분권과 15,016,500주의 공동 의결권 및 처분권을 보유하고 있고, 해당 주식은 Adage Capital Partners, L.P.를 통해 보유하고 있다고 명시되어 있습니다.

제출서에는 해당 증권이 영업의 통상적 범위 내에서 취득 및 보유되었으며 발행인의 지배권을 변경하거나 영향력을 행사하기 위해 취득되지 않았다는 인증이 포함되어 있어, 이는 수동적 투자 의도를 나타냅니다.

Adage Capital Management, L.P., ainsi que Robert Atchinson et Phillip Gross, déclare la propriété bénéficiaire de 15,016,500 actions ordinaires de Wave Life Sciences, représentant 9,65% de la catégorie sur la base de 155,562,665 actions ordinaires en circulation, comme indiqué dans le proxy de la société. Le dépôt est soumis sur le Schedule 13G (Amendement n° 4) et fait état de 0 pouvoir de vote ou de disposition exclusif et de 15,016,500 actions avec pouvoir de vote et de disposition partagé, détenues via Adage Capital Partners, L.P.

Le dépôt inclut une certification selon laquelle les titres ont été acquis et sont détenus dans le cours normal des affaires et n'ont pas été acquis dans le but de modifier ou d'influencer le contrôle de l'émetteur, indiquant une intention d'investissement déclarée comme passive.

Adage Capital Management, L.P., zusammen mit Robert Atchinson und Phillip Gross, meldet wirtschaftliches Eigentum an 15,016,500 Stammaktien von Wave Life Sciences, was 9,65% der Klasse auf Basis von 155,562,665 ausstehenden Stammaktien entspricht, wie im Proxy der Gesellschaft angegeben. Die Einreichung erfolgt auf Schedule 13G (Änderung Nr. 4) und weist 0 alleinige Stimm- oder Verfügungsbefugnis sowie 15,016,500 Aktien mit gemeinsamer Stimm- und Verfügungsbefugnis aus, gehalten über Adage Capital Partners, L.P.

Die Einreichung enthält eine Bestätigung, dass die Wertpapiere im gewöhnlichen Geschäftsverlauf erworben und gehalten wurden und nicht zum Zweck der Änderung oder Beeinflussung der Kontrolle des Emittenten erworben wurden, was eine als passiv bezeichnete Investitionsabsicht anzeigt.

Positive
  • Reporting Persons collectively beneficially own 15,016,500 shares, representing 9.65% of the outstanding ordinary shares as reported in the company's proxy
  • Filing is on Schedule 13G with a certification that the securities were acquired and are held in the ordinary course and not to influence control, indicating declared passive intent
Negative
  • Reporting Persons have 0 shares of sole voting or dispositive power, limiting any unilateral governance control
  • No disclosure of activist intent or plans to change control, which means the sizable stake does not come with an announced strategic or governance agenda

Insights

TL;DR: Adage holds a material 9.65% passive stake (15,016,500 shares) in WVE with shared voting and dispositive power.

The filing discloses a significant ownership position sized at 15,016,500 shares, equal to 9.65% of the reported 155,562,665 outstanding ordinary shares. Ownership is reported as shared voting and dispositive power with 0 shares of sole control, and the Schedule 13G includes a certification that the position is held in the ordinary course and not to influence control. From an investor perspective, this is a material passive stake that should be tracked for any future filings indicating a change in intent or level of control.

TL;DR: Schedule 13G filing indicates passive intent; shared voting/dispositive power is disclosed but no claim of sole control.

The reporting persons are identified as Adage Capital Management, L.P. and two individuals who act as managing members of the relevant Adage entities that hold the shares. The statement explicitly records shared voting and dispositive power over 15,016,500 shares and confirms the holdings were not acquired to change or influence issuer control. This filing therefore communicates a sizable, declaredly passive ownership position rather than an active governance or control campaign.

Adage Capital Management, L.P., insieme a Robert Atchinson e Phillip Gross, segnala la titolarità beneficiaria di 15,016,500 azioni ordinarie di Wave Life Sciences, rappresentanti il 9.65% della categoria in base a 155,562,665 azioni ordinarie in circolazione come indicato nella proxy della società. La comunicazione è presentata sul Schedule 13G (Emendamento n. 4) e riporta 0 poteri di voto o di disposizione in via esclusiva e 15,016,500 azioni con poteri di voto e di disposizione condivisi, detenute tramite Adage Capital Partners, L.P.

La documentazione include una certificazione secondo cui i titoli sono stati acquisiti e sono detenuti nell'ordinario corso dell'attività e non sono stati acquistati per modificare o influenzare il controllo dell'emittente, indicando un intento di investimento dichiaratamente passivo.

Adage Capital Management, L.P., junto con Robert Atchinson y Phillip Gross, comunica la titularidad beneficiaria de 15,016,500 acciones ordinarias de Wave Life Sciences, que representan el 9.65% de la clase sobre la base de 155,562,665 acciones ordinarias en circulación, según consta en el proxy de la compañía. La presentación se realiza en el Schedule 13G (Enmienda n.º 4) y muestra 0 poder exclusivo de voto o de disposición y 15,016,500 acciones con poder de voto y de disposición compartido, mantenidas a través de Adage Capital Partners, L.P.

La presentación incluye una certificación de que los valores fueron adquiridos y se mantienen en el curso ordinario del negocio y no fueron adquiridos para cambiar o influir en el control del emisor, lo que indica una intención de inversión declaradamente pasiva.

Adage Capital Management, L.P.는 Robert Atchinson 및 Phillip Gross와 함께 Wave Life Sciences의 15,016,500 보통주에 대한 실질적 소유를 보고하며, 이는 회사의 프록시에 기재된 155,562,665 발행 보통주를 기준으로 해당 계급의 9.65%에 해당합니다. 이 제출은 Schedule 13G(수정서 4호)로 이루어졌으며, 0의 단독 의결권 또는 처분권과 15,016,500주의 공동 의결권 및 처분권을 보유하고 있고, 해당 주식은 Adage Capital Partners, L.P.를 통해 보유하고 있다고 명시되어 있습니다.

제출서에는 해당 증권이 영업의 통상적 범위 내에서 취득 및 보유되었으며 발행인의 지배권을 변경하거나 영향력을 행사하기 위해 취득되지 않았다는 인증이 포함되어 있어, 이는 수동적 투자 의도를 나타냅니다.

Adage Capital Management, L.P., ainsi que Robert Atchinson et Phillip Gross, déclare la propriété bénéficiaire de 15,016,500 actions ordinaires de Wave Life Sciences, représentant 9,65% de la catégorie sur la base de 155,562,665 actions ordinaires en circulation, comme indiqué dans le proxy de la société. Le dépôt est soumis sur le Schedule 13G (Amendement n° 4) et fait état de 0 pouvoir de vote ou de disposition exclusif et de 15,016,500 actions avec pouvoir de vote et de disposition partagé, détenues via Adage Capital Partners, L.P.

Le dépôt inclut une certification selon laquelle les titres ont été acquis et sont détenus dans le cours normal des affaires et n'ont pas été acquis dans le but de modifier ou d'influencer le contrôle de l'émetteur, indiquant une intention d'investissement déclarée comme passive.

Adage Capital Management, L.P., zusammen mit Robert Atchinson und Phillip Gross, meldet wirtschaftliches Eigentum an 15,016,500 Stammaktien von Wave Life Sciences, was 9,65% der Klasse auf Basis von 155,562,665 ausstehenden Stammaktien entspricht, wie im Proxy der Gesellschaft angegeben. Die Einreichung erfolgt auf Schedule 13G (Änderung Nr. 4) und weist 0 alleinige Stimm- oder Verfügungsbefugnis sowie 15,016,500 Aktien mit gemeinsamer Stimm- und Verfügungsbefugnis aus, gehalten über Adage Capital Partners, L.P.

Die Einreichung enthält eine Bestätigung, dass die Wertpapiere im gewöhnlichen Geschäftsverlauf erworben und gehalten wurden und nicht zum Zweck der Änderung oder Beeinflussung der Kontrolle des Emittenten erworben wurden, was eine als passiv bezeichnete Investitionsabsicht anzeigt.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Adage Capital Management, L.P.
Signature:/s/ Robert Atchinson
Name/Title:By: Adage Capital Partners LLC, its General Partner, By: Robert Atchinson, its Managing Member
Date:08/12/2025
Robert Atchinson
Signature:/s/ Robert Atchinson
Name/Title:Robert Atchinson, individually
Date:08/12/2025
Phillip Gross
Signature:/s/ Phillip Gross
Name/Title:Phillip Gross, individually
Date:08/12/2025

FAQ

How many WVE shares does Adage Capital report owning?

Adage Capital and the reporting persons report beneficial ownership of 15,016,500 shares of Wave Life Sciences.

What percentage of WVE does the 15,016,500 shares represent?

The reported position represents 9.65% of the outstanding ordinary shares, based on 155,562,665 shares reported in the company's proxy.

Does Adage have sole voting or dispositive power over these WVE shares?

No. The filing reports 0 shares of sole voting power and 0 shares of sole dispositive power, with 15,016,500 shares reported as shared voting and dispositive power.

What type of SEC filing was submitted for the WVE position?

The position was disclosed on a Schedule 13G (Amendment No. 4) filing.

Did the filing state whether the stake was acquired to influence control of WVE?

Yes. The filing includes a certification that the securities were acquired and are held in the ordinary course of business and were not acquired to change or influence control of the issuer.
Wave Life Scienc

NASDAQ:WVE

WVE Rankings

WVE Latest News

WVE Latest SEC Filings

WVE Stock Data

1.39B
133.87M
15.89%
82.47%
10.54%
Biotechnology
Pharmaceutical Preparations
Link
Singapore
SINGAPORE